- cafead Sep 23, 2020 at 11:12: AM
via Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease (AD) patients.
That’s the top-line verdict, anyway, after another setback in the field, this time from the phase 2 Tauriel trial of Roche and partner AC Immune’s anti-tau antibody, semorinemab, in early (prodromal to mild) AD.
article source
That’s the top-line verdict, anyway, after another setback in the field, this time from the phase 2 Tauriel trial of Roche and partner AC Immune’s anti-tau antibody, semorinemab, in early (prodromal to mild) AD.
article source